EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer

References

• Ferlay J Shin HR Bray F Forman D Mathers C Parkin DM Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 Int J Cancer 2010 127 2893 2917 21351269
   PubMed Web of Science ®Google Scholar
• Le Péchoux C Role of postoperative radiotherapy in resected non-small cell lung cancer: a reassessment based on new data Oncologist 2011 16 672 681 21378080
   PubMed Web of Science ®Google Scholar
• Wu M Zhao J Song SW EGFR mutations are associated with prognosis but not with the response to front-line chemotherapy in the Chinese patients with advanced non-small cell lung cancer Lung Cancer 2010 67 343 347 19477549
   PubMed Web of Science ®Google Scholar
• van Zandwijk N Giaccone G Treatment of metastatic non-small cell lung cancer Curr Opin Oncol 1996 8 120 125 8727304
   PubMedGoogle Scholar
• Piyathilake CJ Frost AR Manne U Differential expression of growth factors in squamous cell carcinoma and precancerous lesions of the lung Clin Cancer Res 2002 8 734 744 11895903
   PubMed Web of Science ®Google Scholar
• Port JL Kent MS Korst RJ Libby D Pasmantier M Altorki NK Tumor size predicts survival within stage IA non-small cell lung cancer Chest 2003 124 1828 1833 14605056
   PubMed Web of Science ®Google Scholar
• Nicholson RI Gee JM Harper ME EGFR and cancer prognosis Eur J Cancer 2001 37 Suppl 4 S9 S15 11597399
   PubMed Web of Science ®Google Scholar
• Onn A Correa AM Gilcrease M Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer Clin Cancer Res 2004 10 136 143 14734462
   PubMed Web of Science ®Google Scholar
• Lonardo F Dragnev KH Freemantle SJ Evidence for the epidermal growth factor receptor as a target for lung cancer prevention Clin Cancer Res 2002 8 54 60 11801540
   PubMed Web of Science ®Google Scholar
• Larsen AK Ouaret D El Ouadrani K Petitprez A Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis Pharmacol Ther 2011 131 80 90 21439312
   PubMed Web of Science ®Google Scholar
• Lichtenberger BM Tan PK Niederleithner H Ferrara N Petzelbauer P Sibilia M Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development Cell 2010 140 268 279 20141840
   PubMed Web of Science ®Google Scholar
• Yatabe Y Takahashi T Mitsudomi T Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer Cancer Res 2008 68 2106 2111 18381415
   PubMed Web of Science ®Google Scholar
• Barr S Thomson S Buck E Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions Clin Exp Metastasis 2008 25 685 693 18236164
   PubMed Web of Science ®Google Scholar
• Gazdar AF Shigematsu H Herz J Minna JD Mutations and addiction to EGFR: the Achilles ‘heal’ of lung cancers? Trends Mol Med 2004 10 481 486 15464447
   PubMed Web of Science ®Google Scholar
• Pao W Miller VA Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions J Clin Oncol 2005 23 2556 2568 15767641
   PubMed Web of Science ®Google Scholar
• Haneda H Sasaki H Lindeman N A correlation between EGFR gene mutation status and bronchioloalveolar carcinoma features in Japanese patients with adenocarcinoma Jpn J Clin Oncol 2006 36 69 75 16449241
   PubMed Web of Science ®Google Scholar
• Choi YH Lee JK Kang HJ Association between age at diagnosis and the presence of EGFR mutations in female patients with resected non-small cell lung cancer J Thorac Oncol 2010 5 1949 1952 21155184
   PubMed Web of Science ®Google Scholar
• Laack E Simon R Regier M Miliary never-smoking adenocarcinoma of the lung: strong association with epidermal growth factor receptor exon 19 deletion J Thorac Oncol 2011 6 199 202 21178715
   PubMed Web of Science ®Google Scholar
• Lynch TJ Bell DW Sordella R Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 2004 350 2129 2139 15118073
   PubMed Web of Science ®Google Scholar
• Mok TS Wu YL Thongprasert S Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 2009 361 947 957 19692680
   PubMed Web of Science ®Google Scholar
• Paez JG Jänne PA Lee JC EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 2004 304 1497 1500 15118125
   PubMed Web of Science ®Google Scholar
• Cappuzzo F Hirsch FR Rossi E Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer J Natl Cancer Inst 2005 97 643 655 15870435
   PubMed Web of Science ®Google Scholar
• Pao W Miller V Zakowski M EGF receptor gene mutations are common in lung cancer from “never-smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib Proc Natl Acad Sci U S A 2004 101 13306 13311 15329413
   PubMed Web of Science ®Google Scholar
• Hirsch FR Varella-Garcia M McCoy J Southwest Oncology Group Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study J Clin Oncol 2005 23 6838 6845 15998906
   PubMed Web of Science ®Google Scholar
• Hirsch FR Varella-Garcia M Bunn PA Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer J Clin Oncol 2006 24 5034 5042 17075123
   PubMed Web of Science ®Google Scholar
• Giaccone G Herbst RS Manegold C Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial – INTACT 1 J Clin Oncol 2004 22 777 784 14990632
   PubMed Web of Science ®Google Scholar
• Gatzemeier U Pluzanska A Szczesna A Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial J Clin Oncol 2007 25 1545 1552 17442998
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA Therasse P Bogaerts J New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 2009 45 228 247 19097774
   PubMed Web of Science ®Google Scholar
• al-Kattan K Sepsas E Fountain SW Townsend ER Disease recurrence after resection for stage I lung cancer Eur J Cardiothorac Surg 1997 12 380 384 9332915
   PubMed Web of Science ®Google Scholar
• Martin J Ginsberg RJ Venkatraman ES Long-term results of combined-modality therapy in resectable non-small-cell lung cancer J Clin Oncol 2002 20 1989 1995 11956257
   PubMed Web of Science ®Google Scholar
• Martini N Bains MS Burt ME Incidence of local recurrence and second primary tumors in resected stage I lung cancer J Thorac Cardiovasc Surg 1995 109 120 129 7815787
   PubMed Web of Science ®Google Scholar
• Jemal A Siegel R Ward E Cancer statistics, 2008 CA Cancer J Clin 2008 58 71 96 18287387
   PubMed Web of Science ®Google Scholar
• Wang CL Yue DS Zhang ZF Treatment and prognostic analysis of 1638 patients with non-small cell lung cancer Zhonghua Wai Ke Za Zhi 2011 49 618 622 Chinese 22041677
   PubMedGoogle Scholar
• Li Z Yu Y Lu J Analysis of the T descriptors and other prognosis factors in pathologic stage I non-small cell lung cancer in China J Thorac Oncol 2009 4 702 709 19404215
   PubMed Web of Science ®Google Scholar
• Lee YJ Park IK Park MS Activating mutations within the EGFR kinase domain: a molecular predictor of disease-free survival in resected pulmonary adenocarcinoma J Cancer Res Clin Oncol 2009 135 1647 1654 19517135
   PubMed Web of Science ®Google Scholar
• Jeon JH Kang CH Kim HS Seong YW Park IK Kim YT Prognostic and predictive role of epidermal growth factor receptor mutation in recurrent pulmonary adenocarcinoma after curative resection Eur J Cardiothorac Surg Epub 2014 4 22
   Web of Science ®Google Scholar
• Sasaki H Shimizu S Endo K EGFR and erbB2 mutation status in Japanese lung cancer patients Int J Cancer 2006 118 180 184 16003726
   PubMed Web of Science ®Google Scholar
• Kosaka T Yatabe Y Onozato R Kuwano H Mitsudomi T Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma J Thorac Oncol 2009 4 22 29 19096302
   PubMed Web of Science ®Google Scholar
• D’Angelo SP Janjigian YY Ahye N Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1,118 surgical specimens and effects of adjuvant gefitinib and erlotinib J Thorac Oncol 2012 7 1815 1822 23154553
   PubMed Web of Science ®Google Scholar
• Liu WS Zhao LJ Pang QS Prognostic value of epidermal growth factor receptor mutations in resected lung adenocarcinomas Med Oncol 2014 31 771 24248816
   PubMed Web of Science ®Google Scholar
• Kobayashi N Toyooka S Ichimura K Non-BAC component but not epidermal growth factor receptor gene mutation is associated with poor outcomes in small adenocarcinoma of the lung J Thorac Oncol 2008 3 704 710 18594314
   PubMed Web of Science ®Google Scholar
• Kosaka T Yatabe Y Endoh H Kuwano H Takahashi T Mitsudomi T Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications Cancer Res 2004 64 8919 8923 15604253
   PubMed Web of Science ®Google Scholar
• Lim KH Huang MJ Liu HC Kuo HT Tzen CY Hsieh RK Lack of prognostic value of EGFR mutations in primary resected non-small cell lung cancer Med Oncol 2007 24 388 393 17917087
   PubMed Web of Science ®Google Scholar
• Nose N Sugio K Oyama T Association between estrogen receptor-beta expression and epidermal growth factor receptor mutation in the postoperative prognosis of adenocarcinoma of the lung J Clin Oncol 2009 27 411 417 19064969
   PubMed Web of Science ®Google Scholar
• Marks JL Broderick S Zhou Q Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma J Thorac Oncol 2008 3 111 116 18303429
   PubMed Web of Science ®Google Scholar
• Pfister DG Johnson DH Azzoli CG American Society of Clinical Oncology American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003 J Clin Oncol 2004 22 330 353 14691125
   PubMed Web of Science ®Google Scholar
• Schiller JH Harrington D Belani CP Eastern Cooperative Oncology Group Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 2002 346 92 98 11784875
   PubMed Web of Science ®Google Scholar
• Fossella F Pereira JR von Pawel J Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group J Clin Oncol 2003 21 3016 3024 12837811
   PubMed Web of Science ®Google Scholar
• Scagliotti GV De Marinis F Rinaldi M Italian Lung Cancer Project Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer J Clin Oncol 2002 20 4285 4291 12409326
   PubMed Web of Science ®Google Scholar
• Kelly K Crowley J Bunn PAJr Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non – small-cell lung cancer: a Southwest Oncology Group trial J Clin Oncol 2001 19 3210 3218 11432888
   PubMed Web of Science ®Google Scholar
• Mok T Wu YL Thongprasert S Phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer (IPASS) Ann Oncol 2008 19 Suppl 8 viiil Abstract LBA2
   Google Scholar
• Fukoka M Wu YL Thongprasert S Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS) J Clin Oncol 2011 29 2866 2874 21670455
   PubMed Web of Science ®Google Scholar
• Han JY Par K Sim SW First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung J Clin Oncol 2012 30 1122 1128 22370314
   PubMed Web of Science ®Google Scholar
• Bell DW Lynch TJ Haserlat SM Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials J Clin Oncol 2005 23 8081 8092 16204011
   PubMed Web of Science ®Google Scholar
• Eberhard DA Johnson BE Amler LC Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib J Clin Oncol 2005 23 5900 5909 16043828
   PubMed Web of Science ®Google Scholar
• Hotta K Kiura K Toyooka S Clinical significance of epidermal growth factor receptor gene mutations on treatment outcome after first-line cytotoxic chemotherapy in Japanese patients with non-small cell lung cancer J Thorac Oncol 2007 2 632 637 17607119
   PubMed Web of Science ®Google Scholar
• Kalikaki A Koutsopoulos A Hatzidaki D Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status Lung Cancer 2010 69 110 115 19854533
   PubMed Web of Science ®Google Scholar
• Dong X Zhao X Hao Y Wei Y Yin Q Du J Response to first-line chemotherapy in patients with non-small-cell lung cancer according to epidermal growth factor receptor and K-RAS mutation status Clin Lung Cancer 2013 14 680 687 23910066
   PubMed Web of Science ®Google Scholar
• Park JH Lee SH Keam B EGFR mutations as a predictive marker of cytotoxic chemotherapy Lung Cancer 2012 77 433 437 22521649
   PubMed Web of Science ®Google Scholar
• Lee KH Han SW Hwang PG Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-small-cell lung cancer Jpn J Clin Oncol 2006 36 334 350 16751651
   PubMed Web of Science ®Google Scholar
• Takano T Fukui T Ohe Y EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan J Clin Oncol 2008 26 5589 5595 18794545
   PubMed Web of Science ®Google Scholar
• Yoshimasu T Oura S Ohta F Epidermal growth factor receptor mutations are associated with docetaxel sensitivity in lung cancer J Thorac Oncol 2011 6 1658 1662 21681119
   PubMed Web of Science ®Google Scholar
• Tsao MS Sakurada A Cutz JC Erlotinib in lung cancer – molecular and clinical predictors of outcome N Engl J Med 2005 353 133 144 16014883
   PubMed Web of Science ®Google Scholar
• Maemondo M Inoue A Kobayashi K North-East Japan Study Group Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N Engl J Med 2010 362 2380 2388 20573926
   PubMed Web of Science ®Google Scholar
• Sugio K Uramoto H Onitsuka T Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations Lung Cancer 2009 64 314 318 18992959
   PubMed Web of Science ®Google Scholar
• Kim ES Hirsh V Mok T Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial Lancet 2008 372 1809 1818 19027483
   PubMed Web of Science ®Google Scholar
• Douillard JY Shepherd FA Hirsh V Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial J Clin Oncol 2010 28 744 752 20038723
   PubMed Web of Science ®Google Scholar
• Wu JY Shih JY Yang CH Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer Int J Cancer 2010 126 247 255 19536777
   PubMed Web of Science ®Google Scholar
• Shepherd FA Tsao MS Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy J Clin Oncol 2006 24 1219 1220 16505443
   PubMed Web of Science ®Google Scholar
• Gazdar AF Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors Oncogene 2009 28 Suppl 1 S24 S31 19680293
   PubMed Web of Science ®Google Scholar
• Sharma SV Bell DW Settleman J Haber DA Epidermal growth factor receptor mutations in lung cancer Nat Rev Cancer 2007 7 169 181 17318210
   PubMed Web of Science ®Google Scholar
• Chintala L Kurzrock R Epidermal growth factor receptor mutation and diverse tumors: case report and concise literature review Mol Oncol 2010 4 306 308 20346742
   PubMed Web of Science ®Google Scholar
• Cappuzzo F Ligorio C Toschi L EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) J Thorac Oncol 2007 2 423 429 17473658
   PubMed Web of Science ®Google Scholar
• Jackman DM Yeap BY Sequist LV Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib Clin Cancer Res 2006 12 3908 3914 16818686
   PubMed Web of Science ®Google Scholar
• Riely GJ Pao W Pham DK Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib Clin Cancer Res 2006 12 839 844 16467097
   PubMed Web of Science ®Google Scholar
• Rosell R Moran T Queralt C Spanish Lung Cancer Group Screening for epidermal growth factor receptor mutations in lung cancer N Engl J Med 2009 361 958 967 19692684
   PubMed Web of Science ®Google Scholar
• Yang J Sequist L Schuler M Overall survival (OS) in patients with advanced non-small cell lung cancer (NSCLC) harbouring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut): pooled analysis of two large open-label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6] comparing afatinib with chemotherapy Abstract #8004. Presented at: 2014 American Society of Clinical Oncology, 50th Annual Meeting May 30–June 3, 2014 Chicago, IL
   Google Scholar
• Mitsudomi T Morita S Yatabe Y West Japan Oncology Group Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (WJTOG3405): an open label, randomized phase 3 trial Lancet Oncol 2010 11 121 128 20022809
   PubMed Web of Science ®Google Scholar
• Mitsudomi T Morita S Yatabe Y Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR) J Clin Oncol 2012 30 suppl abstr 7521
   Google Scholar
• Shigematsu H Lin L Takahashi T Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers J Natl Cancer Inst 2005 97 339 346 15741570
   PubMed Web of Science ®Google Scholar
• Mukohara T Engelman JA Hanna NH Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations J Natl Cancer Inst 2005 97 1185 1194 16106023
   PubMed Web of Science ®Google Scholar
• Bean J Brennan C Shih JY MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib Proc Natl Acad Sci U S A 2007 104 20932 20937 18093943
   PubMed Web of Science ®Google Scholar
• Sequist LV Waltman BA Dias-Santagata D Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors Sci Transl Med 2011 3 75ra26
   PubMed Web of Science ®Google Scholar
• Chmielecki J Foo J Oxnard GR Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling Sci Transl Med 2011 3 90 90ra59
   PubMed Web of Science ®Google Scholar
• Rosell R Molina MA Costa C Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations Clin Cancer Res 2011 17 1160 1168 21233402
   PubMed Web of Science ®Google Scholar
• Chmielecki J Foo J Oxnard GR Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling Sci Transl Med 2011 3 90ra59
   PubMed Web of Science ®Google Scholar
• Yun CH Mengwasser KE Toms AV The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP Proc Natl Acad Sci U S A 2008 105 2070 2075 18227510
   PubMed Web of Science ®Google Scholar
• Kobayashi S Boggon TJ Dayaram T EGFR mutation and resistance of non-small-cell lung cancer to gefitinib N Engl J Med 2005 352 786 792 15728811
   PubMed Web of Science ®Google Scholar
• Pao W Miller VA Politi KA Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain PLoS Med 2005 2 e73 15737014
   PubMed Web of Science ®Google Scholar
• Yu HA Arcila ME Rekhtman N Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers Clin Cancer Res 2013 19 2240 2247 23470965
   PubMed Web of Science ®Google Scholar
• Oxnard GR Arcila ME Sima CS Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation Clin Cancer Res 2011 17 1616 1622 21135146
   PubMed Web of Science ®Google Scholar
• Fujita Y Suda K Kimura H Highly sensitive detection of EGFR T790M mutation using colony hybridization predicts favorable prognosis of patients with lung cancer harboring activating EGFR mutation J Thorac Oncol 2012 7 1640 1644 22899358
   PubMed Web of Science ®Google Scholar
• Kuiper JL Heideman DA Thunnissen E Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients Lung Cancer 2014 85 19 24 24768581
   PubMed Web of Science ®Google Scholar
• Li W Ren S Li J T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients Lung Cancer 2014 84 295 300 24685306
   PubMed Web of Science ®Google Scholar
• Sun JM Ahn MJ Choi YL Ahn JS Park K Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors Lung Cancer 2013 82 294 298 24035188
   PubMed Web of Science ®Google Scholar
• Ding D Yu Y Li Z Niu X Lu S The predictive role of pretreatment epidermal growth factor receptor T790M mutation on the progression-free survival of tyrosine-kinase inhibitor-treated non-small cell lung cancer patients: a meta-analysis Onco Targets Ther 2014 7 387 393 24623981
   PubMed Web of Science ®Google Scholar
• Walter AO Tjin R Haringsma H CO-1686, an orally available, mutant-selective inhibitor of the epidermal growth factor receptor (EGFR) causes tumor shrinkage in non-small cell lung cancer (NSCLC) with T790M mutations Mol Cancer Ther 2011 11 Suppl 1 C189
   Google Scholar
• Zhou W Ercan D Chen L Novel mutant-selective EGFR kinase inhibitors against EGFR T790M Nature 2009 462 1070 1074 20033049
   PubMed Web of Science ®Google Scholar
• Clovis Oncology, Inc Study to Evaluate Safety, Pharmacokinetics, and Efficacy of CO-1686 in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients Available from: http://www.clinicaltrials.gov/show/NCT01526928. NLM identifier: NCT01526928 Accessed April 13, 2013
   Google Scholar
• Ranson M Pao W Kim D An irreversible, potent and selective tyrosine kinase inhibitor (TKI) of activating (EGFRM+) and resistance (T790M) mutations in advanced NSCLC J Thorac Oncol 2014 8 Suppl 2 S389
   Google Scholar
• Sequist LV Soria JC Gadgeel SM First-in-human evaluation of CO-1686, an irreversible, selective, and potent tyrosine kinase inhibitor of EGFR T790M J Clin Oncol 2013 31 Suppl 31 abstr 2524
   Google Scholar
• Ranson M Pao W Kim D Preliminary results from a Phase I study with AZD9291: An irreversible inhibitor of epidermal growth factor receptor (EGFR) activating and resistance mutations in non-small-cell lung cancer (NSCLC) Eur J Cancer 2013 49 Suppl 3 S15
   Google Scholar
• Janjigian YY Smit EF Groen HJ Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations Cancer Discov 2014 4 1036 1045 25074459
   PubMed Web of Science ®Google Scholar
• Zhou C Wu YL Chen G Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicenter, open-label, randomized, phase 3 study Lancet Oncol 2011 12 735 742 21783417
   PubMed Web of Science ®Google Scholar
• Rosell R Carcereny E Gervais R Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial Lancet Oncol 2012 13 239 246 22285168
   PubMed Web of Science ®Google Scholar
• Inoue A Kobayashi K Maemondo M North-East Japan Study Group Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002) Ann Oncol 2013 24 54 59 22967997
   PubMed Web of Science ®Google Scholar
• Gao G Ren S Li A Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: a meta-analysis from six phase III randomized controlled trials Int J Cancer 2012 131 E822 E829 22161771
   PubMed Web of Science ®Google Scholar
• Sequist LV Yang JC Yamamoto N Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations J Clin Oncol 2013 31 3327 3334 23816960
   PubMed Web of Science ®Google Scholar
• Wu YL Zhou C Hu CP Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial Lancet Oncol 2014 15 213 222 24439929
   PubMed Web of Science ®Google Scholar
• Paz-Ares L Soulières D Klughammer B Bara I Moecks J Mok T Pooled analysis of clinical outcomes for patients with EGFR mutations in non-small cell lung cancer: an update Ann Oncol 2012 23 Suppl 9 abstract 1254P
   Google Scholar
• Petrelli F Borgonovo K Cabiddu M Barni S Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small-cell lung cancer: a meta-analysis of 13 randomized trials Clin Lung Cancer 2012 13 107 114 22056888
   PubMed Web of Science ®Google Scholar
• Liang W Wu X Fang W Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations PLoS One 2014 9 e85245 24533047
   PubMed Web of Science ®Google Scholar
• Kris MG Mok T Ignatius SH First-line dacomitinib (PF-00299804), an irreversible pan-HER tyrosine kinase inhibitor, for patients with EGFR-mutant lung cancers J Clin Oncol 2012 30 suppl abstr 7530
   Google Scholar
• Lara-Guerra H Waddell TK Salvarrey MA Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer J Clin Oncol 2009 27 6229 6236 19884551
   PubMed Web of Science ®Google Scholar
• Roberts PJ Stinchcombe TE Der CJ Socinski MA Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? J Clin Oncol 2010 28 4769 4777 20921461
   PubMed Web of Science ®Google Scholar
• Sordella R Bell DW Haber DA Settleman J Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways Science 2004 305 1163 1167 15284455
   PubMed Web of Science ®Google Scholar
• Chou TY Chiu CH Li LH Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer Clin Cancer Res 2005 11 3750 3757 15897572
   PubMed Web of Science ®Google Scholar
• Wu JY Yu CJ Chang YC Yang CH Shih JY Yang PC Effectiveness of tyrosine kinase inhibitors on “uncommon” epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer Clin Cancer Res 2011 17 3812 3821 21531810
   PubMed Web of Science ®Google Scholar
• Xu JM Han Y Duan HQ EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with gefitinib J Cancer Res Clin Oncol 2009 135 771 782 19020901
   PubMed Web of Science ®Google Scholar
• Xing K Zhou X Zhao X A novel point mutation in exon 20 of EGFR showed sensitivity to erlotinib Med Oncol 2014 31 36 24908064
   PubMed Web of Science ®Google Scholar
• Berge EM Aisner DL Doebele RC Erlotinib response in an NSCLC patient with a novel compound G719D+L861R mutation in EGFR J Thorac Oncol 2013 8 e83 e84 23945392
   PubMed Web of Science ®Google Scholar